MannKind is trading 5% up at $4.08 after recovering from the August 6 selloff following its second-quarter results, as revenue reached $109.4 million, up 43% year over year.
- Furoscix sales rose sequentially, and management highlighted progress across its commercial pipeline.
- Investors appear to be reassessing the growth outlook despite a $19.0 million net loss, higher launch spending, and an EPS miss.
- The broader biotech sector’s 2.09% gain and risk-on market backdrop provided additional support.